Cargando…
Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice
Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341470/ https://www.ncbi.nlm.nih.gov/pubmed/32642871 http://dx.doi.org/10.1186/s13568-020-01051-1 |
_version_ | 1783555246805483520 |
---|---|
author | Xiao, Jiameng Liu, Jianfang Bao, Chuntong Zhu, Rining Gu, Jingmin Sun, Changjiang Feng, Xin Du, Chongtao Han, Wenyu Li, Yang Lei, Liancheng |
author_facet | Xiao, Jiameng Liu, Jianfang Bao, Chuntong Zhu, Rining Gu, Jingmin Sun, Changjiang Feng, Xin Du, Chongtao Han, Wenyu Li, Yang Lei, Liancheng |
author_sort | Xiao, Jiameng |
collection | PubMed |
description | Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine. Consequently, epitope-based vaccines conferring Actinobacillus pleuropneumoniae cross protection have rarely been reported. In this study, B cell epitopes in the head domain of trimeric autotransporter adhesin were predicted, and 6 epitopes were selected. Then, the predicted epitopes (Ba1, Bb5, C1, PH1 and PH2) were connected by linkers to construct a recombinant tandem antigen (rta) gene. The RTA protein encoded by the recombinant rta gene was expressed, and finally the ICR mice were immunized with the RTA protein with or without inactivated Actinobacillus pleuropneumoniae (serovars 1 and 5b) and challenged with Actinobacillus pleuropneumoniae to evaluate the protective effect of the epitope-based vaccine and combined vaccine. The mice in the RTA-immunized group and RTA plus inactivated Actinobacillus pleuropneumoniae vaccine group had a significant improvement in clinical symptoms and a higher level of antibody in the serum than those in the control group. The RTA immune group had a 40% survival rate after Actinobacillus pleuropneumoniae infection, whereas the combination of RTA and inactivated Actinobacillus pleuropneumoniae produced very strong cross immune protection in mice, at least 50% (RTA IB1 + C5) and at most 100% (RTA IB5 + C1), whereas no cross immunoprotection was found in the solo Actinobacillus pleuropneumoniae immune group. Overall, the combination of the RTA protein and inactivated bacteria significantly enhanced the cross protection effects. This implies that RTA protein in combination with a suitable inactivated Actinobacillus pleuropneumoniae strain could be a candidate vaccine for porcine contagious pleuropneumonia. |
format | Online Article Text |
id | pubmed-7341470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-73414702020-07-08 Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice Xiao, Jiameng Liu, Jianfang Bao, Chuntong Zhu, Rining Gu, Jingmin Sun, Changjiang Feng, Xin Du, Chongtao Han, Wenyu Li, Yang Lei, Liancheng AMB Express Original Article Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine. Consequently, epitope-based vaccines conferring Actinobacillus pleuropneumoniae cross protection have rarely been reported. In this study, B cell epitopes in the head domain of trimeric autotransporter adhesin were predicted, and 6 epitopes were selected. Then, the predicted epitopes (Ba1, Bb5, C1, PH1 and PH2) were connected by linkers to construct a recombinant tandem antigen (rta) gene. The RTA protein encoded by the recombinant rta gene was expressed, and finally the ICR mice were immunized with the RTA protein with or without inactivated Actinobacillus pleuropneumoniae (serovars 1 and 5b) and challenged with Actinobacillus pleuropneumoniae to evaluate the protective effect of the epitope-based vaccine and combined vaccine. The mice in the RTA-immunized group and RTA plus inactivated Actinobacillus pleuropneumoniae vaccine group had a significant improvement in clinical symptoms and a higher level of antibody in the serum than those in the control group. The RTA immune group had a 40% survival rate after Actinobacillus pleuropneumoniae infection, whereas the combination of RTA and inactivated Actinobacillus pleuropneumoniae produced very strong cross immune protection in mice, at least 50% (RTA IB1 + C5) and at most 100% (RTA IB5 + C1), whereas no cross immunoprotection was found in the solo Actinobacillus pleuropneumoniae immune group. Overall, the combination of the RTA protein and inactivated bacteria significantly enhanced the cross protection effects. This implies that RTA protein in combination with a suitable inactivated Actinobacillus pleuropneumoniae strain could be a candidate vaccine for porcine contagious pleuropneumonia. Springer Berlin Heidelberg 2020-07-08 /pmc/articles/PMC7341470/ /pubmed/32642871 http://dx.doi.org/10.1186/s13568-020-01051-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Xiao, Jiameng Liu, Jianfang Bao, Chuntong Zhu, Rining Gu, Jingmin Sun, Changjiang Feng, Xin Du, Chongtao Han, Wenyu Li, Yang Lei, Liancheng Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title | Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title_full | Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title_fullStr | Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title_full_unstemmed | Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title_short | Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice |
title_sort | recombinant tandem epitope vaccination provides cross protection against actinobacillus pleuropneumoniae challenge in mice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341470/ https://www.ncbi.nlm.nih.gov/pubmed/32642871 http://dx.doi.org/10.1186/s13568-020-01051-1 |
work_keys_str_mv | AT xiaojiameng recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT liujianfang recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT baochuntong recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT zhurining recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT gujingmin recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT sunchangjiang recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT fengxin recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT duchongtao recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT hanwenyu recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT liyang recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice AT leiliancheng recombinanttandemepitopevaccinationprovidescrossprotectionagainstactinobacilluspleuropneumoniaechallengeinmice |